U.S. markets open in 2 hours 45 minutes

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
85.92+0.92 (+1.08%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close85.00
Open84.98
Bid0.00 x 1100
Ask0.00 x 1100
Day's Range82.55 - 88.21
52 Week Range18.76 - 126.90
Volume614,815
Avg. Volume824,325
Market Cap5.377B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.76
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est93.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 2 Winners for a Drug Development Future That Looks Nothing Like the Past
    Motley Fool

    2 Winners for a Drug Development Future That Looks Nothing Like the Past

    In hindsight, the pandemic may have been that turning point for gene-based medicine. The authorization of the first vaccines using messenger RNA validated a segment of the life sciences industry that seemed destined for some futuristic version of healthcare. Genome sequencing and gene editing have been around for several years.

  • Beam Therapeutics Is Ready to Beam Higher
    TheStreet.com

    Beam Therapeutics Is Ready to Beam Higher

    Beam Therapeutics is pioneering the use of base editing - a potential new class of precision genetic medicines. This is way above my pay grade so let's look at the charts of BEAM. In this daily bar chart of BEAM, below, we can see that prices made a base in the $20-$30 area before rallying to a high in February above $120.

  • Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference

    CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:30 a.m. ET. The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. Contacts: Investors:Chelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com Media:Dan Budwick1ABdan@1abmedia.com